IASO Biotherapeutics Publishes Preclinical Results of Its CD5-Targeting CAR-T in American Society of Gene & Cell Therapy’s Journal, Molecular Therapy
Retrieved on:
Wednesday, August 18, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Dai, RRMM, CAR, Publishing, Program, Efficiency, Research, Huazhong University of Science and Technology, MCL, Epitope, Mutation, Risk, Chronic lymphocytic leukemia, Genetics, Hematopoietic stem cell transplantation, CD5, Medicine, VH, CRISPR, CMC, T-ALL, CLL, Paper, Cell, Huachung University, TCL, Technology, Cell therapy, Hope, Antibody, NMPA, Biotechnology, Degenerative disease, Fragment crystallizable region, Neoplasm, Tongji Hospital station, Molecular Therapy, Gene, Thymocyte, Transplant, Cancer, Society, Antigen, Mantle cell lymphoma, Chemistry, Gene editing, Multimedia, Western literature, Leukemia, HSCT, Patient, Vaccine
View the full release here: https://www.businesswire.com/news/home/20210818005265/en/
Key Points:
- View the full release here: https://www.businesswire.com/news/home/20210818005265/en/
Screenshot of IASO Bios published preclinical results (source: cell.com) (Graphic: Business Wire)
Molecular Therapy is the official periodical of the American Society of Gene & Cell Therapy, and is published under Cell. - In recent years, CAR-T technology has seen numerous breakthroughs and achieved tremendous progress with the development of targets for the treatment B cell malignancies.
- T cell malignancies include T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoma (TCL)1.
- CD5 is also expressed in certain B cell malignancies, making CD5 a valid target for the treatment of both T cell and B cell malignancies.